NEW YORK, NY (May 7, 2013) -- Type 1 (insulin-dependent) diabetes appears to increase the risk of heart disease, the leading cause of death among people with high blood sugar, partly by stimulating the production of calprotectin, a protein that sparks an inflammatory process that fuels the buildup of artery-clogging plaque. The findings, made in mice and confirmed with human data, suggest new therapeutic targets for reducing heart disease in people with type 1 diabetes. Led by Columbia University Medical Center (CUMC) researchers in collaboration with investigators at New York University and the University of Pittsburgh, the study was published today in the online edition of Cell Metabolism.
Diabetes is known to raise the risk for atherosclerosis, a disease in which fatty deposits known as plaque accumulate inside arteries. Over time, the arteries harden and narrow, leading to coronary artery disease and other forms of heart disease. Atherosclerosis is the leading cause of heart attacks, strokes, and peripheral vascular disease--collectively known as coronary heart disease, the leading cause of death in the United States.
Scientists have known that diabetes leads to atherosclerosis. The study shows that this is associated with increased circulating levels of inflammatory white blood cells (WBCs), which contribute to the build-up of plaque. "But exactly how diabetes causes white blood cells to proliferate and lead to heart disease has been a mystery," said study co-leader Ira J. Goldberg, MD, Dickinson W. Richards Professor of Medicine at CUMC.
In studies of mice with type 1 diabetes, Dr. Goldberg and his colleagues found that high blood sugar stimulates a type of inflammatory WBC known as neutrophils to release the protein calprotectin (also known as S100A8/9). The calprotectin travels to the bone marrow, where it binds to a cell-surface receptor called RAGE receptor, on common myeloid progenitor cells, which are involved in the production of various types of blood cells. This, in turn, leads to the proliferation of cells, known as granulocyte macrophage progenitor cells, which trigger the proliferation of even more neutrophils and of monocytes (another type of inflammatory WBC). Finally, these new WBCs enter the circulation and make their way to arterial plaques, fueling their progression.
The researchers also found that normalizing the mice's blood glucose dampened this pathway, leading to an overall decrease in inflammation.
To determine the relevance of these findings in humans, the researchers analyzed data from 290 patients in the Pittsburgh Epidemiology of Diabetes Complications (EDC) Study, led by EDC Principal Investigator Trevor J. Orchard, who has been following people with diabetes for 18 years. Total WBC, neutrophil, and monocyte counts were all significantly associated with the development of coronary artery disease. The researchers also analyzed blood samples from a subgroup of EDC patients. Those who had developed coronary artery disease had significantly higher levels of calprotectin, compared with patients who had not developed coronary artery disease.
"The human data appear to fit with the animal data, in that both WBCs and calprotectin are associated with heart disease," said co-lead author Andrew J. Murphy, PhD, postdoctoral fellow in medicine at CUMC. The other lead author is Prabhakara R. Nagareddy, PhD, postdoctoral fellow at CUMC.
"Our findings point to the importance of controlling blood levels to limit the production of inflammatory cells that drive atherosclerosis; they also suggest novel therapeutic strategies, such as inhibiting the production of calprotectin or preventing its binding to the RAGE receptor," said study co-leader Alan R. Tall, MD, the Tilden Weger Bieler Professor of Medicine at CUMC.
The CUMC team is currently studying how type 2 diabetes increases one's risk for heart disease.
The paper is titled, "Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis." The other contributors are Roslynn A. Stirzaker (CUMC), Yunying Hu (CUMC), Shiuqing Yu (CUMC), Rachel G. Miller (University of Pittsburgh, Pittsburgh, Penn.), Bhama Ramkhelawon New York University, New York, NY), Emilie Distel (NYU), Marit Westerterp (CUMC), Li-Shin Huang (CUMC), Ann Marie Schmidt (NYU), and Edward A.Fisher (NYU).
This research was supported by grants from the National Institutes of Health (U01-21 HL087945, DK095684 and DK048412; and P01 HL54591, and R01 HL107653, a Pilot and Feasibility Award from the Diabetes Complications Consortium, and postdoctoral fellowships from the Canadian Institutes of Health Research and the American Heart Association. A portion of funds supporting this research was obtained from Bristol-Myers Squibb Pharmaceuticals. The authors declare no other financial or conflicts of interest.
Columbia University Medical Center provides international leadership in basic, pre-clinical, and clinical research; medical and health sciences education; and patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Columbia University Medical Center is home to the largest medical research enterprise in New York City and state and one of the largest faculty medical practices in the Northeast. For more information, visit cumc.columbia.edu or columbiadoctors.org.
Resources for related information:
Elizabeth Streich, 212-305-3689, email@example.com
Karin Eskenazi, 212-342-0508, firstname.lastname@example.org